Precision Medicine in Antidepressants Treatment
- PMID:37195310
- DOI: 10.1007/164_2023_654
Precision Medicine in Antidepressants Treatment
Erratum in
- Correction to: Precision Medicine in Antidepressants Treatment.Tsermpini EE, Serretti A, Dolžan V.Tsermpini EE, et al.Handb Exp Pharmacol. 2023;280:283. doi: 10.1007/164_2023_661.Handb Exp Pharmacol. 2023.PMID:37458808No abstract available.
Abstract
Precision medicine uses innovative approaches to improve disease prevention and treatment outcomes by taking into account people's genetic backgrounds, environments, and lifestyles. Treatment of depression is particularly challenging, given that 30-50% of patients do not respond adequately to antidepressants, while those who respond may experience unpleasant adverse drug reactions (ADRs) that decrease their quality of life and compliance. This chapter aims to present the available scientific data that focus on the impact of genetic variants on the efficacy and toxicity of antidepressants. We compiled data from candidate gene and genome-wide association studies that investigated associations between pharmacodynamic and pharmacokinetic genes and response to antidepressants regarding symptom improvement and ADRs. We also summarized the existing pharmacogenetic-based treatment guidelines for antidepressants, used to guide the selection of the right antidepressant and its dose based on the patient's genetic profile, aiming to achieve maximum efficacy and minimum toxicity. Finally, we reviewed the clinical implementation of pharmacogenomics studies focusing on patients on antidepressants. The available data demonstrate that precision medicine can increase the efficacy of antidepressants and reduce the occurrence of ADRs and ultimately improve patients' quality of life.
Keywords: Antidepressants; Candidate genes; Genome-wide association studies; Pharmacogenetics; Pharmacogenomics; Precision medicine.
© 2023. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Similar articles
- Clinical implementation of preemptive pharmacogenomics in psychiatry: Τhe "PREPARE" study.Tsermpini EE, Skokou M, Ferentinos P, Georgila E, Gourzis P, Assimakopoulos K, Patrinos GP; U-PGx Group in Greece.Tsermpini EE, et al.Psychiatriki. 2020 Oct-Dec;31(4):341-351. doi: 10.22365/jpsych.2020.314.341.Psychiatriki. 2020.PMID:33361064
- Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade.Alessandrini M, Chaudhry M, Dodgen TM, Pepper MS.Alessandrini M, et al.OMICS. 2016 Oct;20(10):593-603. doi: 10.1089/omi.2016.0122. Epub 2016 Sep 19.OMICS. 2016.PMID:27643672Free PMC article.Review.
- Antidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic tools.Bousman CA, Forbes M, Jayaram M, Eyre H, Reynolds CF, Berk M, Hopwood M, Ng C.Bousman CA, et al.BMC Psychiatry. 2017 Feb 8;17(1):60. doi: 10.1186/s12888-017-1230-5.BMC Psychiatry. 2017.PMID:28178974Free PMC article.Review.
- Pharmacogenomics for personalized pain medicine.Ko TM, Wong CS, Wu JY, Chen YT.Ko TM, et al.Acta Anaesthesiol Taiwan. 2016 Mar;54(1):24-30. doi: 10.1016/j.aat.2016.02.001. Epub 2016 Mar 11.Acta Anaesthesiol Taiwan. 2016.PMID:26976339Review.
- Genetics and personalized medicine in antidepressant treatment.Gvozdic K, Brandl EJ, Taylor DL, Müller DJ.Gvozdic K, et al.Curr Pharm Des. 2012;18(36):5853-78. doi: 10.2174/138161212803523617.Curr Pharm Des. 2012.PMID:22681166Review.
Cited by
- Are There Biological Correlates of Response to Yoga-Based Interventions in Depression? A Critical Scoping Review.Rajkumar RP.Rajkumar RP.Brain Sci. 2024 May 25;14(6):543. doi: 10.3390/brainsci14060543.Brain Sci. 2024.PMID:38928543Free PMC article.
- Serotonin transporter 5-HTTLPR polymorphism and escitalopram treatment response in patients with major depressive disorder.Jarčušková D, Tkáč I, Hlaváčová N, Yaluri AS, Kozárová M, Habalová V, Klimčáková L, Židzik J, Javorský M, Bednářová A.Jarčušková D, et al.BMC Psychiatry. 2024 Oct 15;24(1):690. doi: 10.1186/s12888-024-06162-8.BMC Psychiatry. 2024.PMID:39407134Free PMC article.
References
- Abaut AY, Chevanne F, Le Corre P (2007) Oral bioavailability and intestinal secretion of amitriptyline: role of P-glycoprotein? Int J Pharm 330:121–128.https://doi.org/10.1016/J.IJPHARM.2006.09.026 - DOI - PubMed
- Adkins DE, Clark SL, Åberg K et al (2012) Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D. Transl Psychiatry 2.https://doi.org/10.1038/TP.2012.57
- Amare AT, Schubert KO, Tekola-Ayele F et al (2018) Association of the polygenic scores for personality traits and response to selective serotonin reuptake inhibitors in patients with major depressive disorder. Front Psych 9.https://doi.org/10.3389/FPSYT.2018.00065
- Angus JA, Black JW (1980) Pharmacological assay of cardiac H2-receptor blockade by amitriptyline and lysergic acid diethylamide. Circ Res 46
- Arndt P, Volk C, Gorboulev V et al (2001) Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1. Am J Physiol Renal Physiol 281.https://doi.org/10.1152/AJPRENAL.2001.281.3.F454
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical